Reference is made to the announcement made by NorDiag ASA ("NorDiag" or the "Company") on 9 December with final results of the rights issue and the conversion issue in the Company. The following table gives an overview of the primary insiders that have been allocated shares in the rights issue and the conversion issue.

Shares allocated in the rights issue at NOK 0.08 per share

Shares allocated in the rights issue at NOK 0.056 per share
Shares allocated in the conversion issue at NOK 0.056 per share
Shareholding in the Company after the rights issue and the conversion issue

Mårten Wigstøl through Barracuda Invest AS, CEO
946,802
2,149,680
331,831
3,688,128

Tone Kvåle, CFO, (including related party)
9,125,000
 
1,118,437
10,883,057

Erik Hornes, CSO
625,000
994,437
167,774
1,897,827

Jan Olav Wikstén, VP Sales and Marketing Europe
312,500
 
22,019
336,519

Guttorm Osborg, VP Instruments and Automation
625,000
 
44,643
669,643

Stein Rune Kjelby, Chief Accountan

625,000
 
41,482
698,863

Robert V. Ahlgren, Chairman of the Board of Directors
11,250,000
 
773,469
12,331,863

Hans Hekland through Hannibal Invest AS, Vice Chairman of the Board of Directors

3,364,284 
867,528 
752,938 
5,907,954

Ann-Kristin Hageløkken, Member of the Board of Directors
625,000
 
44,643
669,643

Mathias Uhlen, Member of the Board of Directors
8,125,000
 
574,364
8,760,759

 
For further information, please contact:
CEO Mårten Wigstøl,   Phone: +47 911 65775
CFO Tone Kvåle,  Phone: +47 915 19576
 
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden and in Atlanta (GA), USA. The group has today 31.6 man-labour years. NorDiag is listed on the Oslo Stock Exchange with ticker NORD.
 
For further information - www.nordiag.com.

Read the notice in Norwegian here.